BMRN Q1 2025 Earnings — BioMarin Pharmaceutical Inc. Revenue & Financial Results | Market Cap Arena

BMRNBioMarin Pharmaceutical Inc.

$12B

Q1 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$745M+14.8% YoY

Gross Profit

$594M79.7% margin

Operating Income

$224M30.0% margin

Net Income

$186M24.9% margin

EPS (Diluted)

$0.95

QoQ Revenue Growth

-0.3%

Cash Flow

Operating Cash Flow

$174M

Free Cash Flow

$158M

Stock-Based Comp.

$38M

Balance Sheet

Total Assets

$7.1B

Total Liabilities

$1.4B

Stockholders' Equity

$5.8B

Cash & Equivalents

$1.0B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$745M	$649M	+14.8%
Gross Profit	$594M	$524M	+13.4%
Operating Income	$224M	$88M	+153.1%
Net Income	$186M	$89M	+109.4%

Revenue Segments

Product

$735M99%

Royalty And Other

$11M1%